| ANTIGEN AND TUMOR CELL TARGETS | ANTIGEN FUNCTION | NAKED ANTIBODIES |
|---|---|---|
| Antigen: CD20 | Proliferation/differentiation | Rituximab (chimeric) |
| Tumor type: B-cell lymphoma and CLL | ||
| Antigen: CD52 | Unknown | Alemtuzumab (humanized) |
| Tumor type: B-cell CLL and T-cell lymphoma | ||
| Antigen: CD25 alpha subunit | Activation antigen | Daclizumab (humanized) |
| Tumor type: T-cell mycosis fungoides | ||
| Antigen: CD33 | Unknown | Gemtuzumab (humanized) |
| Tumor type: acute myeloid leukemia | ||
| Antigen: HER2/neu (ErbB-2) | Tyrosine kinase | Trastuzumab (humanized) |
| Tumor type: breast cancer | ||
| Antigen: EGFR (ErbB-1) | Tyrosine kinase | Cetuximab (chimeric) |
| Tumor type: colorectal; NSCLC; pancreatic, breast | ||
| Antigen: VEGF | Angiogenesis | Bevacizumab (humanized) |
| Tumor type: colorectal cancer |
Thursday, October 15, 2009
54 - Monoclonal antibodies approved for Hematological and Solid tumors
Subscribe to:
Posts (Atom)
Subscribe Now: Feed
You are visitor number
